A Study of F0002-ADC in Chinese Patients With Refractory or Recurrent CD30+ Hematologic Malignancies.

NCT03894150 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

45

Enrollment

INDUSTRY

Sponsor class

Conditions

Refractory or Recurrent CD30+ Hematologic Malignancies

Interventions

DRUG: F0002-ADC

Sponsor

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.